Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...

Full description

Bibliographic Details
Main Authors:	Xiaoyan Liu, Yitian Lang, Yahui Liao, Yizhun Zhu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Public Health
Subjects:	atezolizumab cost-effectiveness partitioned survival model triple-negative breast cancer the perspective of China
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.756899/full

Similar Items

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022-08-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020-06-01)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
by: Luciana Molinero, et al.
Published: (2019-10-01)

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
by: Dongfeng Feng, et al.
Published: (2021-05-01)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
by: K. Sharmni Vishnu, et al.
Published: (2022-11-01)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
by: Enrique Grande, et al.
Published: (2023-12-01)

Opportunities for metastatic triple negative breast cancer therapy
by: Inna P. Ganshina, et al.
Published: (2021-05-01)

Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis
by: Yitian Lang, et al.
Published: (2023-09-01)

Eosinophilic Fasciitis in a Patient Treated by Atezolizumab for Metastatic Triple-Negative Breast Cancer
by: Yacine Wissam, et al.
Published: (2019-06-01)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
by: Yujing Xin, et al.
Published: (2022-08-01)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01)

Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells
by: Nishant Mohan, et al.
Published: (2019-09-01)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
by: Chuan Zhang, et al.
Published: (2023-03-01)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
by: J. A. Kyte, et al.
Published: (2020-06-01)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024-04-01)

Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
by: Matheus Sewastjanow-Silva, et al.
Published: (2024-03-01)

Fulminant myocarditis during postoperative adjuvant chemotherapy for lung cancer with atezolizumab: a case report
by: Takuya Tokunaga, et al.
Published: (2024-03-01)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
by: Seung Ho Baek, et al.
Published: (2022-06-01)

Platinum chemotherapy for early triple-negative breast cancer
by: Sofia RE. Mason, et al.
Published: (2024-06-01)

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis
by: Xueyan Liang, et al.
Published: (2023-05-01)

Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature
by: Mihoko Imaji, et al.
Published: (2021-05-01)

New chemotherapy options for triple-negative breast cancer (review of literature)
by: M A Sekundova, et al.
Published: (2014-03-01)

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
by: Yitian Lang, et al.
Published: (2024-02-01)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
by: Chien-Yu Tseng, et al.
Published: (2023-11-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
by: Ken Masubuchi, et al.
Published: (2022-10-01)

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
by: Sang Youn Hwang, et al.
Published: (2024-02-01)

Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer
by: Peter F.G. Foulser, et al.
Published: (2022-01-01)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
by: Alaa M. Ghallab, et al.
Published: (2022-04-01)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
by: Sun Hyun Bae, et al.
Published: (2023-09-01)

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review
by: Yuxin Ma, et al.
Published: (2024-03-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
by: Tomoyuki Satake, et al.
Published: (2023-07-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023-09-01)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
by: Yuetong Liu, et al.
Published: (2023-04-01)

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
by: Jin Sothornwit, et al.
Published: (2019-06-01)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
by: Shuanghe Li, et al.
Published: (2022-10-01)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
by: Hideki Iwamoto, et al.
Published: (2022-07-01)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
by: Nikolai A. Ognerubov, et al.
Published: (2021-08-01)